The Biocon share rallied over 8% to touch a fresh 52-week high of Rs 444.50 on the NSE. The sharp upstick in the stock came after buzz about a large block deal.

The difference could be seen in the trading volume as well, which skyrocketed 180 times today comparatively. The company’s trading volume (NSE+BSE) stood at 8 crore shares, while the one-month average trading volume is 42 lakh shares. 

According to a Reuters report last evening, Mylan, ​part of a global healthcare ‌company Viatris plans to sell up to 92 million shares in Biocon worth up to Rs 3,481 crore. Reuters report quioting sources had indiocated that the ​sale could potentially represent up to 5.64% of ​Biocon’s outstanding shares. 

Financialexpress.com could not verify the news independently.

Biocon share price performance

The share price of Biocon has risen 7% in the last five trading days. The stock has given a return of over 5% in the past one month and 15.55% in the last six monts. Biocon’s share price has surged 15% over the previous 12 months. 

Biocon Q4FY26 results

The company’s consolidated net profit fell 63% year-on-year to Rs 126 crore in Q4FY26. The company took an exceptional charge of Rs 80 crore during the quarter, mainly related to one-time adjustments and restructuring impacts tied to business integration. However, the net profit before exceptional items surged 64% YoY to Rs 179 crore.

Its operating revenue rose 10% YoY to Rs 4,517 crore in Q4FY26, while EBITDA came in at Rs 1,073 crore, reflecting a 29% increase on a YoY basis, supported by improved product mix and operating leverage.